NEW YORK, May 29, 2024 /PRNewswire/ -- Remedy Pharmaceuticals, a pioneer in stroke drug development, announced that prespecified subgroup analyses from the Phase 3 CHARM clinical trial of CIRARA (IV glibenclamide) showed meaningful improvements in functional outcomes on the modified Rankin Scale (mRS), which were further validated in post hoc analyses.
Enforcement Report - Week of August 22, 2018
NEW DELHI: India’s central drug regulator has told drug makers and state regulators to ensure that essential medicines are available to patients across the country, following reported incidents of shortages in drugs following the Goods and Services Tax implementation.